Georgia's Online Cancer Information Center

Find A Clinical Trial

A Study of RGX-104 in Patients With Advanced Solid Malignancies and Lymphoma

Status
Active
Cancer Type
Gynecologic Cancers
Lung Cancer
Lymphoma
Neuroendocrine Tumor
Ovarian Cancer
Primary Peritoneal Cancer
Solid Tumor
Trial Phase
Phase I
Eligibility
18 Years and older, Male and Female
Study Type
Treatment
NCT ID
NCT02922764
Protocol IDs
RGX-104-001 (primary)
NCI-2017-00226
Study Sponsor
Inspirna, Inc.

Summary

Study RGX-104-001 is a Phase 1, first-in-human, dose escalation and expansion study of
RGX-104, an oral small molecule targeting the liver X receptor (LXR), as a single agent and
in combination with nivolumab, ipilimumab, docetaxel, or pembrolizumab plus
carboplatin/pemetrexed. RGX-104 activates LXR, resulting in depletion of both myeloid-derived
suppressor cells (MDSCs) as well as tumor blood vessels. MDSCs block the ability of T-cells
and other cells of the immune system from attacking tumors.

During the dose escalation stage, multiple doses and schedules of orally administered RGX-104
with or without nivolumab, ipilimumab, docetaxel, or pembrolizumab plus
carboplatin/pemetrexed (single agent or combination therapy) will be evaluated in patients
with advanced solid tumors and lymphoma (i.e., locally advanced and unresectable, or
metastatic) who have had progressive disease (PD) on available standard systemic therapies or
for which there are no standard systemic therapies of relevant impact. Dose escalation in
combination with pembrolizumab plus carboplatin/pemetrexed will be restricted to patients
with non-small cell lung cancer (NSCLC).

In the expansion stage of the study, additional patients with epithelial ovarian carcinoma
(EOC), NSCLC, or small cell lung cancer (SCLC)/high-grade neuroendocrine tumors (HG-NET) will
be treated at the MTD (or maximum tested dose if no MTD is identified, or dose below the MTD
if there is evidence suggesting a more favorable risk/benefit profile). This stage will
provide further characterization of the safety, efficacy, PK, and pharmacodynamics, including
biomarkers of immunologic activity and LXR target activation, of RGX-104 as a single agent
(EOC), in combination with docetaxel (SCLC/HG-NET), and and in combination with pembrolizumab
plus carboplatin/pemetrexed (NSCLC).

Eligibility

  1. The patient must have histologic or cytologic evidence of a malignant solid tumor or lymphoma (any histology) and must have advanced disease, defined as cancer that is either metastatic or locally advanced and unresectable (and for which additional radiation therapy or other locoregional therapies are not considered feasible).
  2. With the exception of dose escalation with pembrolizumab plus carboplatin/pemetrexed, patients enrolled in the dose escalation stages must have disease that is resistant to or relapsed following available standard systemic therapy, or for which there is no standard systemic therapy or reasonable therapy in the physician's judgment likely to result in clinical benefit or if such therapy has been refused by the patient. Documentation of the reason must be provided for patients who have not received a standard therapy likely to result in clinical benefit.
  3. Patients enrolled in the expansion stages must agree to a tumor biopsy to be obtained during the screening period and toward the beginning of Cycle 2 or at the time of PD, if earlier. If a biopsy is deemed by the investigator to not be in the patient's best interest, prior approval must be obtained from the Medical Monitor to waive this requirement.
  4. The patient must have disease that is measurable by standard imaging techniques per RECIST or immune-related response criteria (irRC; all tumor types except lymphoma) or International Working Group (IWG) revised response criteria for malignant lymphoma (lymphoma only). For patients with prior radiation therapy, measurable lesions must be outside of any prior radiation field(s), unless disease progression has been documented at that disease site subsequent to radiation.
  5. The patient is =18 years old.
  6. The patient has an ECOG PS of =1.
  7. The patient has adequate baseline organ function, as demonstrated by the following:
  8. Serum creatinine =1.5 × institutional upper limit of normal (ULN) or calculated creatinine clearance >30 mL/min (>45 ml/min for patients receiving carboplatin/pemetrexed).
  9. Serum albumin =2.5 g/dl;
  10. Bilirubin =1.5 × institutional ULN.
  11. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =2.5 × institutional ULN. Patients enrolled in an expansion stage may have ALT and AST < 5 × institutional ULN if the patient has hepatic metastases;
  12. For patients not taking warfarin or other oral anticoagulants: international normalized ratio (INR) =1.5 or prothrombin time (PT) =1.5 × ULN; and either partial thromboplastin time or activated partial thromboplastin time (PTT or aPTT) =1.5 × ULN. Patients taking warfarin should be on a stable dose that results in a stable INR <3.5. Among patients receiving other oral anticoagulant therapy, PT or aPTT must be within the intended therapeutic range of the anticoagulant.
  13. The patient has adequate baseline hematologic function, as demonstrated by the following:
  14. Absolute neutrophil count (ANC) =1.5×109/L;
  15. Hemoglobin =8 g/dL and no red blood cell (RBC) transfusions during the prior 14 days;
  16. Platelet count =100×109/L and no platelet transfusions during the prior 14 days.
  17. The patient has a normal left ventricular ejection fraction (LVEF) per institutional criteria as determined by either echocardiography (ECHO) or multigated acquisition (MUGA) scanning.
  18. If the patient is a woman of child-bearing potential (WOCBP), she has had a negative serum or urine pregnancy test within 2 weeks prior to treatment.
  19. The patient (men and WOCBP) agrees to use acceptable contraceptive methods for the duration of time on the study, and continue to use acceptable contraceptive methods for 1 month after the last dose of study therapy. Patients receiving combination therapy must agree to use acceptable contraceptive methods for the duration of time on the study and continue to use acceptable contraceptive methods for 6 months after the last dose of study therapy.
  20. The patient has signed informed consent prior to initiation of any study-specific procedures or treatment.
  21. The patient is able to adhere to the study visit schedule and other protocol requirements, including follow-up for survival assessment.
  22. Tumor tissue (a minimum of 10 and up to 15 unstained slides, or paraffin block, ideally from the patient's most recent biopsy, must be made available prior to the first dose of study therapy.
  23. For patients with EOC enrolled in the single agent expansion stage:
  24. The patient must have a pathologically confirmed (by histology or cytology) diagnosis of epithelial ovarian, fallopian tube or primary peritoneal carcinoma, which is currently recurrent or persistent Stage 3 or Stage 4 disease. A histologic diagnosis of borderline, low malignant potential epithelial carcinoma is not permitted.
  25. The patient must have received an appropriate platinum-based chemotherapy in the first line setting.
  26. If the patient has platinum-sensitive relapsed disease (first relapse > 6 months from end of initial platinum therapy), the patient should have been re-treated with platinum for relapsed disease (or be intolerant or have refused such treatment).
  27. The patient may not have received treatment with immune checkpoint inhibitors (e.g., products that target PD-L1, PD-1, or CTLA-4).
  28. The patient must not have required a paracentesis within the preceding 4 weeks nor be projected to require a paracentesis within the next 8 weeks.
  29. For patients with NSCLC enrolled in the pembrolizumab plus carboplatin/pemetrexed combination dose escalation or expansion stages:
  30. The patient must have histologic or cytologic evidence of newly-diagnosed non-squamous, NSCLC that is advanced disease, defined as cancer that is either metastatic (Stage 4) or locally advanced (Stage 3B) and unresectable.
  31. The patient has confirmation that epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK)-directed therapy is not indicated.
  32. The patient has not received prior systemic treatment for their advanced/metastatic disease.
  33. For patients in the expansion stage only: the patient's tumor block must demonstrate PD-L1 expression TPS <1% as determined with a validated assay.
  34. The patient must have adequate organ function and performance status eligible for treatment with a platinum-based regimen and checkpoint inhibitor.
  35. For patients with SCLC enrolled in the docetaxel combination expansion stage:
  36. The patient must have a pathologically confirmed (by histology or cytology) diagnosis of SCLC, which is currently extensive disease (disease outside a single radiation port), or of metastatic neuroendocrine cancer with small cell or high-grade features. Patients with metastatic neuroendocrine cancer with small cell or high-grade features must have a pathology report supplied to the sponsor before treatment.
  37. The patient must have demonstrated disease progression following platinum-based chemotherapy with or without a PD-1/L1 inhibitor for SCLC, or following a different, acceptable first-line regimen for high-grade neuroendocrine tumors.
  38. The patient must have received no more than 1 prior line of therapy for extensive disease.

Treatment Sites in Georgia

Winship Cancer Institute of Emory University


1365 Clifton Road NE
Building C
Atlanta, GA 30322
404-778-5180
winshipcancer.emory.edu

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.
Georgia CORE

 

Advancing Cancer Care through Partnerships and Innovation

Georgia CORE is a statewide nonprofit that leverages partnerships and innovation to attract more clinical trials, increase research, and promote education and early detection to improve cancer care for Georgians in rural, urban, and suburban communities across the state.